Research article

Dynamics of a stochastic HBV infection model with cell-to-cell transmission and immune response

Xiaoqin Wang¹,*, Yiping Tan¹, Yongli Cai², Kaifa Wang³ and Weiming Wang²,*

¹ School of Arts and Science, Shaanxi University of Science and Technology Shaanxi, Xi’an 710021, China
² School of Mathematics and Statistics, Huaiyin Normal University, Huaiian 223300, China
³ School of Mathematics and Statistics, Southwest University, Chongqing 400715, China

* Correspondence: Email: wangxiaojin@sust.edu.cn, weimingwang2003@163.com.

Abstract: In this paper, considering the proven role of exosomes and the inevitable randomization within-host, we establish a hepatitis B virus (HBV) model with cell-to-cell transmission and CTL immune response from a deterministic framework to a stochastic differential equation (SDE). By introducing the reproduction number $R_0$, we prove that $R_0$ can be used to govern the stochastic dynamics of the SDE HBV model. Under certain assumptions, if $R_0 \leq 1$, the solution of the SDE model always fluctuates around the infection-free equilibrium of the deterministic model, which indicates that the HBV will eventually disappear almost surely; if $R_0 > 1$, under extra conditions, the solution of the SDE model fluctuates around endemic equilibrium of the corresponding deterministic model, which leads to the stochastic persistence of the HBV with probability one. One of the most interesting findings is that the fluctuation amplitude is positively related to the intensity of the white noise, which can provide us some useful control strategies to regulate HBV infection dynamics.

Keywords: HBV infection model; immune response; cell-to-cell transmission; asymptotic behavior

1. Introduction

Hepatitis B, including acute and chronic disease, is caused by the hepatitis B virus (HBV) infection and has become a major global health problem. World Health Organization (WHO) estimates that in 2019, 325 million people globally live with hepatitis B and/or C, while in 2015, 257 million people were living with chronic hepatitis B infection (defined as hepatitis B surface antigen positive), of them, 887,000 deaths, mostly from cirrhosis and hepatocellular carcinoma (i.e., primary liver cancer) [1].

Generally, cellular immunopathological reaction plays an important role in controlling HBV infection. For example, cytotoxic T lymphocytes (CTLs) can specifically attack the target infected
host cells [2], which will induce hepatocyte damage. And more and more attentions have been paid to the study of virus dynamics within-host, which can provide insights into virus infection and dynamics, as well as to how an infection can be reduced or even eradicated, see [3–7] and the references therein.

Studies have shown that human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can spread by two fundamental modes within-host, one by virus-to-cell infection through the extracellular space and the other by cell-to-cell transfer involving direct cell-to-cell contact [4, 8–16]. Especially, Sourisseau et al. [17] had reported that viral transfer in vitro via cell-to-cell contact is much more rapid and efficient than infection by free virus because it avoids several biophysical and kinetic barriers. Monel et al. [18] showed that direct cell-to-cell transmission in vivo is also more potent and more efficient. And Yang and co-authors [19] showed a previously unappreciated role of exosomes in HBV transmission and natural killer cells dysfunction during chronic hepatitis B (CHB) infection. These results showed that cell-to-cell transmission is reasonable apart from virus-to-cell mode in HBV infection because exosomes can transfer genetic material between cells. Therefore, during HBV infection, uninfected hepatocytes can be infected not only by newly released free virus, but also by contacting with infected hepatocytes. Combining with the CTLs population, to describe HBV from a single patient’s point of view, we first propose the following HBV infection model:

\[
\begin{align*}
\frac{dx}{dt} &= \lambda_1 - d_1x - \beta_1xv - \beta_2xy, \\
\frac{dy}{dt} &= \beta_1xv + \beta_2xy - ay - pyz, \\
\frac{dv}{dt} &= ky - \gamma v, \\
\frac{dz}{dt} &= \lambda_2 - d_2z + qyz,
\end{align*}
\]

where \(x, y, v, z\) denote the total numbers of uninfected hepatocytes, infected hepatocytes, free virus and CTLs, respectively. It is assumed that normal hepatocytes are produced by bone marrow and other organs at a constant rate of \(\lambda_1\) and the natural death rate is \(d_1\). \(\beta_1\) is the effective contact rate between uninfected hepatocytes and virus, \(\beta_2\) stands for the effective contact rate between uninfected and infected hepatocytes, \(a\) represents the natural death rate of the infected hepatocytes. Infected hepatocytes are eliminated by CTLs at rate \(pyz\), free virus are produced from infected cells at rate \(ky\) and die at rate \(\gamma v\). CTLs are produced at a constant \(\lambda_2\) from the thymus, and at rate \(qyz\) due to the stimulation of infected cells [20], and die at rate \(d_2z\).

Note that there are inevitably random disturbances in the process of HBV infection within-host, such as temperature fluctuation, mood fluctuation and other physiological rhythm changes, which may affect the dynamics of HBV infection. Thus, in addition to the traditional ordinary differential equations (ODEs), such as model (1), more attention has been paid to the stochastic differential equations (SDEs) which takes Brownian motion into consideration [21–31] and the references therein. Concretely, [31] was about HIV infection and did not consider cell-to-cell transmission. Especially, references [5, 26, 32] investigated the stochastic dynamics of HBV infection. After assuming the total number of hepatocytes is constant, Bertacchi et al. [5] proposed a stochastic HBV model for the infection within a patient which was treated with two drugs, either sequentially or contemporaneously, developed a two-step mutation which was resistant to both drugs, and studied the deterministic approximation of the stochastic model and gave a biological interpretation of its
asymptotic behaviour. Luzyanina and Bocharov [26] considered a reduced ODEs model which only describes the interaction between the HBV and the CTL response, and Xie et al. [32] investigated the stochastic HBV dynamics. Unfortunately, these studies had not considered the CTL response and cell-to-cell transmission in their SDE HBV model.

Thanks to the insightful work of Luzyanina and Bocharov [26], we know that the variations can affect either the replication of the virus or its elimination kinetics, e.g., via parameters $\beta_2$, $\gamma$ and $d_2$, respectively. And we can explore their impacts on the dynamics of HBV infection could be the extension of the deterministic description of the virus—CTL interaction to include the stochastic forcing in a multiplicative way.

To investigate the influence of fluctuating (vs. constant) rates $\beta_2$, $\gamma$ and $d_2$ on the model solutions, following [26], we randomize these parameters as follows.

Let $p \in [p_1, p_2]$ be a parameter being randomized and $p_1, p_2$ are its low and upper bounds. We assume that $p$ varies randomly according to $p(t) = \bar{p} + \sigma p \xi(t)$, where $\bar{p}$ is the value of $p$ around which we randomize, $\xi(t)$ is a standard Gaussian random variable for each $t$ and $\sigma p > 0$ is the intensity of the noise. We adopt $\sigma p$ as

$$\sigma p = \frac{\min(\bar{p} - p_1, p_2 - \bar{p})}{3}$$

to ensure that $p$ remains in the interval $[p_1, p_2]$ with probability 0.997. This implies that about 99.7% of values drawn from a normal distribution are within three standard deviations $\sigma p$ away from the mean.

More precisely, let

$$\beta_2 \rightarrow \beta_2 + \sigma_1 dB_1(t), \quad \gamma \rightarrow \gamma + \sigma_2 dB_2(t), \quad d_2 \rightarrow d_2 + \sigma_3 dB_3(t),$$

then, corresponding to the deterministic model (1), we can further derive the following SDE HBV model:

$\begin{align*}
    dx &= (\lambda_1 - d_1 x - \beta_1 x v - \beta_2 x y)dt - \sigma_1 x y dB_1(t), \\
    dy &= (\beta_1 x v + \beta_2 x y - a y - p y z)dt + \sigma_1 x y dB_1(t), \\
    dv &= (k y - \gamma v)dt - \sigma_2 y dB_2(t), \\
    dz &= (\lambda_2 - d_2 z + g y z)dt - \sigma_3 z dB_3(t),
\end{align*}$

(2)

where $\sigma_i (i = 1, 2, 3)$ represent the intensities of the white noises, and $B_i(t)$ ($i = 1, 2, 3$) are independent standard Brownian motions.

It is worthy to note that, if the number of individuals in the population gets very large, Kurtz [33, 34] proved that if there is a density-dependent stochastic jump process (such as the number of viral particles, the infected/uninfected hepatocytes etc.), then the process that we obtain when rescaling by a constant and large quantity can be approximated by the solution of the corresponding ODE.

The purpose of the present study is to elaborate the virus infection dynamics to random perturbations in the virus replication and immune responses parameters. In the next section, we give the global dynamics of the deterministic HBV model (1), including the basic reproduction number and global stability of infection-free equilibrium and infection equilibrium. In Section 3, we show the existence and uniqueness of the global positive solutions of the SDE HBV model (2). In Section 4, we give the asymptotic property of the positive solution of model (2) around infection-free equilibrium. And in Section 5, the dynamics of the stochastic model around infection equilibrium is obtained. In Section 6, numerical simulations of model (2) illustrate the correctness of the theoretical results and the correlation between fluctuation amplitude and intensity of the white noise is further studied. In Section 7, we discuss our new findings in the view of epidemiological implications.

Mathematical Biosciences and Engineering Volume 18, Issue 1, 616–642.
2. Global threshold dynamics of the deterministic model (1)

We are interested in the dynamics of viral infection rather than the initial processes of infection. The initial condition of model (1) is assumed as the form \(x(0) > 0, y(0) > 0, v(0) > 0\) and \(z(0) > 0\). Based on the initial conditions, it is clear that the solutions of model (1) are non-negative and ultimately bounded. Model (1) always has an infection-free equilibrium \(E_0 = (x_0, 0, 0, z_0)\), where \(x_0 = \frac{\lambda_1}{d_1}\), \(z_0 = \frac{\lambda_2}{d_2}\). According to the definition and algorithm of the basic reproduction number of virus in [35], we can obtain the basic reproduction number of model (1) as follows:

\[
R_0 := \frac{\lambda_1 d_2 \left( \frac{\lambda_0}{\gamma} + \beta_2 \right)}{d_1 (ad_2 + \lambda_2 p)}. \tag{3}
\]

Obviously, \(R_0\) increases as \(\beta_1\) and \(\beta_2\) increasing.

After some algebraic operations, it is easy to know that, if \(R_0 > 1\), model (1) has an infection equilibrium \(E^* = (x^*, y^*, v^*, z^*)\), where

\[
x^* = \frac{\lambda_1}{d_1 + \beta y^*}, \quad v^* = \frac{k y^*}{\gamma}, \quad z^* = \frac{\lambda_1 \beta}{p (d_1 + \beta y^*)} - \frac{a}{p},
\]

and \(y^*\) is the positive root of Eq (4) in \((0, (R_0 - 1)d_1)\):

\[
a \beta q y^2 = [\beta (\lambda_2 p + ad_2) + q (\lambda_1 \beta - ad_1)] y - d_1 (ad_2 + \lambda_2 p)(R_0 - 1). \tag{4}
\]

On the global stability of the equilibria of model (1), we have the following results.

**Theorem 2.1.** For model (1), if \(R_0 \leq 1\), \(E_0\) is globally asymptotically stable. If \(R_0 > 1\), \(E^*\) is globally asymptotically stable and \(E_0\) is unstable.

**Proof.** We first prove the global stability of the disease-free equilibrium \(E_0\).

Define a Lyapunov function

\[
L_1(x, y, v, z) = x - x_0 - x_0 \ln \frac{x}{x_0} + y + mv + \frac{p}{q} \left( z - z_0 - z_0 \ln \frac{z}{z_0} \right),
\]

where \(m\) will be determined below.
Taking the time derivative of $L_1(x, y, v, z)$ with respect to the solution of model (1), we can obtain:

$$L_1'(1) = \lambda_1 \left( \frac{x}{x_0} - d_1 x - \beta_1 x v - \beta_2 x y \right) + \beta_1 x v + \beta_2 x y - a y - p y z + m(k y - y v)$$

$$+ \frac{p(z-z_0)}{q z} \left( \lambda_2 - d z + q y z \right)$$

$$= (x - x_0) \left( \lambda_1 \left( \frac{1}{x} - \frac{1}{x_0} \right) - \beta_1 v - \beta_2 y \right) + \frac{p(z-z_0)}{q} \left( \frac{1}{z} - \frac{1}{z_0} \right)$$

$$+ m(k y - y v) + p y (z - z_0) + (\beta_1 (x - x_0) v + \beta_2 (x - x_0) y - p y (z - z_0)$$

$$+ (\beta_2 x_0 - a - p z_0) y) + \beta_1 x_0 v$$

$$= \lambda_1 \left( \frac{1}{x} - \frac{1}{x_0} \right) (x - x_0) + \frac{p(z-z_0)}{q} \left( \frac{1}{z} - \frac{1}{z_0} \right) + (\beta_2 x_0 - a - p z_0 + mk) y$$

$$+ (\beta_1 x_0 - m y) v.$$ 

When $R_0 \leq 1$, we obtain $\frac{\beta_1 x_0}{\gamma} \leq \frac{a + p z_0 - \beta_2 x_0}{k}$, so there exists $m$ satisfying

$$\frac{\beta_1 x_0}{\gamma} \leq m \leq \frac{a + p z_0 - \beta_2 x_0}{k},$$

such that

$$\beta_2 x_0 - a - p z_0 + mk \leq 0, \quad \beta_1 x_0 - m y \leq 0.$$ 

Then

$$L_1'(1) \leq \lambda_1 \left( \frac{1}{x} - \frac{1}{x_0} \right) (x - x_0) + \frac{p(z-z_0)}{q} \left( \frac{1}{z} - \frac{1}{z_0} \right)$$

$$\leq 0.$$ 

Let $M_1 = \{ (x, y, v, z) \mid L_1'(1) \}$. We can know that $L_1'(1) = 0$ if and only if $x = x_0$, $y = 0$, $v = 0$, $z = z_0$. Hence, $M_1 = \{ E_0 \}$. Therefore it follows from Lyapunov-Lasalle invariance principle that $E_0$ is globally asymptotically stable when $R_0 \leq 1$.

Next, we prove the global stability of the positive equilibrium $E^*$.

Consider the following Lyapunov function:

$$L_2(x, y, v, z) = x - x^* - x^* \ln \frac{x}{x^*} + \left( y - y^* - y^* \ln \frac{y}{y^*} \right)$$

$$+ \frac{\beta_1 x^* v^*}{k y^*} \left( v - v^* - v^* \ln \frac{v}{v^*} \right) + \frac{p}{q} \left( z - z^* - z^* \ln \frac{z}{z^*} \right).$$

At the infection equilibrium $E^*$, we can get:

$$\lambda_1 = d_1 x^* + \beta_1 x^* v^* + \beta_2 x^* y^*, \quad a = \frac{\beta_1 x^* v^*}{y^*} + \beta_2 x^* - p z^*, \quad \gamma = \frac{k y^*}{v^*}, \quad d_2 = \frac{\lambda_2}{z^*} + q y^*. \quad (5)$$
Taking the time derivation of $L_2(x, y, v, z)$ along with the solution of model (1), and considering Eq (5), we can obtain:

$$L_2'(1) = \left(1 - \frac{x}{x^*}\right)(-d_1(x - x^*) - \beta_1(xv - x^*v^*) - \beta_2(xy - x^*y^*)) + (y - y^*)(\beta_1\left(\frac{xy}{y^*} - \frac{x^*v^*}{y^*}\right) + \beta_2(x - x^*) - p(z - z^*)) + \frac{\beta_1x^*v^*}{y^*}(v - v^*)(\frac{y}{v} - \frac{y^*}{v^*}) + \frac{p}{q}(z - z^*)\left(\lambda_2\left(\frac{1}{z} - \frac{1}{z^*}\right) + q(y - y^*)\right).$$

Let $x_1 = \frac{x}{x^*}, y_1 = \frac{y}{y^*}, v_1 = \frac{v}{v^*}, z_1 = \frac{z}{z^*}$, then

$$L_2'(1) = -d_1x^*(x_1 - 1)\left(1 - \frac{1}{x_1}\right) - \beta_1x^*v^*(x_1v_1 - 1)\left(1 - \frac{1}{x_1}\right) - \beta_2x^*v^*(x_1y_1 - 1)\left(1 - \frac{1}{x_1}\right) + \beta_1x^*v^*(y_1 - 1)\left(\frac{x_1v_1}{y_1} - 1\right) + \beta_2x^*v^*(y_1 - 1)(x_1 - 1) + \frac{p\lambda_2}{q}(z_1 - 1)^2 + x^*(2 - x_1) + \frac{p\lambda_2}{q}(2 - z_1 - \frac{1}{z_1}) + \beta_1x^*v^*(3 - \frac{1}{x_1} - \frac{x_1v_1}{y_1} - \frac{y_1}{v_1}).$$

Since the arithmetical mean $\frac{mn}{2}$ of $m$ and $n$ is greater than or equal to their geometrical mean $\sqrt{mn}$, it follows that $L_2'(1) \leq 0$. Let $M^* = \{(x, y, v, z) \mid L_2'(1) = 0\}$. We note that $L_2'(1) = 0$ if and only if $x_1 = 1, y_1 = v_1, z_1 = 1$, i.e., $x = x^*, y = y^*, v = v^*$, $z = z^*$. Easy to know, $z = y^*, v = v^*$. So the largest invariant set of model (1) on the set $M^*$ is the singleton $\{E^*\}$. By the Lasalle principle, when $R_0 > 1$, the infection equilibrium $E^*$ is globally asymptotically stable.

The proof is completed. □

**Remark 1.** From Theorem 2.1, we know that $R_0$ can be used to govern the threshold dynamics of deterministic HBV model (1). That is, if $R_0 \leq 1$, the HBV infection will go to extinction; while if $R_0 > 1$, the HBV infection will persist.

3. The existence and uniqueness of the solution of the SDE model (2)

**Theorem 3.1.** For any initial value $X(0) = (x(0), y(0), v(0), z(0)) \in \mathbb{R}^4_+$, there exist positive constants $N_1$ and $N_2$ such that the set $\Omega$ is almost surely positively invariant of the SDE HBV model (2), where

$$\Omega = \left\{X(t) \in \mathbb{R}^4_+ : 0 < x(t) + y(t) \leq \Lambda, 0 < v(t) \leq N_1, 0 < x(t) + y(t) + \frac{p}{q}z(t) \leq N_2\right\}.$$
and

\[ \Lambda := \frac{\lambda_1}{\min\{a, d_1\}}. \]

**Proof.** It is clear that all solutions of model (2) starting from \( \mathbb{R}_+^4 = \{(x, y, v, z) : x(0) > 0, y(0) > 0, v(0) > 0, z(0) > 0\} \) are non-negative. From the first two equations of model (2), we have

\[
d(x + y) \leq (\lambda_1 - d_1 x - ay)dt \leq (\lambda_1 - \min\{a, d_1\})(x + y)dt,
\]

which implies

\[
\limsup_{t \to +\infty} (x(t) + y(t)) \leq \frac{\lambda_1}{\min\{a, d_1\}} := \Lambda.
\]

From the third equation of model (2), we have

\[
dv \leq (k\Lambda - \gamma v)dt - \sigma_2vdB_2(t).
\]

It follows that

\[
v(t) \leq \frac{k\Lambda}{\gamma} + \left( v(0) - \frac{k\Lambda}{\gamma} \right) e^{-\gamma t} - \sigma_2 \int_0^t e^{-\gamma(t-s)}v(s)dB_2(s) := X_1(t),
\]

where

\[
X_1(t) = v(0) + A_1(t) - C_1(t) + \tilde{M}_1(t),
\]

and

\[
A_1(t) = \frac{k\Lambda}{\gamma} (1 - e^{-\gamma t}),
\]

\[
C_1(t) = v(0) (1 - e^{-\gamma t}),
\]

\[
\tilde{M}_1(t) = -\sigma_2 \int_0^t e^{-\gamma(t-s)}v(s)dB_2(s).
\]

Clearly, \( A_1(t) \) and \( C_1(t) \) are continuous adapted increasing process on \( t \geq 0 \) with \( A_1(0) = C_1(0) = 0 \).

By [36, Theorem 1.3.9, p.14], we can obtain

\[
\lim_{t\to+\infty} X_1(t) < \infty \ a.s.
\]

That is, \( \lim_{t\to+\infty} v(t) < \infty \ a.s. \), which means that there is a positive constant \( N_1 \) such that

\[
v(t) \leq N_1, \forall t \geq 0 \ a.s.
\]
It follows that

\[ x(t) + y(t) + \frac{p}{q}z(t) \leq \frac{\lambda_1 + \frac{pl_k}{q}}{\min\{a, d_1, d_2\}} + \left( x(0) + y(0) + \frac{p}{q}z(0) - \frac{\lambda_1 + \frac{pl_k}{q}}{\min\{a, d_1, d_2\}} \right) e^{-\min\{a, d_1, d_2\}t} \]

\[ -\frac{p\sigma_3}{q} \int_0^t e^{-\min\{a, d_1, d_2\}|t-s|} z(s) dB_3(s) := X_2(t), \]

where

\[ X_2(t) = x(0) + y(0) + \frac{p}{q}z(0) + A_2(t) - C_2(t) + \tilde{M}_2(t), \]

and

\[ A_2(t) = \frac{\lambda_1 + \frac{pl_k}{q}}{\min\{a, d_1, d_2\}} \left( 1 - e^{-\min\{a, d_1, d_2\}t} \right), \]

\[ C_2(t) = \left( x(0) + y(0) + \frac{p}{q}z(0) \right) \left( 1 - e^{-\min\{a, d_1, d_2\}t} \right), \]

\[ \tilde{M}_2(t) = -\frac{p\sigma_3}{q} \int_0^t e^{-\min\{a, d_1, d_2\}|t-s|} z(s) dB_3(s). \]

Clearly, \( A_2(t) \) and \( C_2(t) \) are continuous adapted increasing process on \( t \geq 0 \) with \( A_2(0) = C_2(0) = 0 \). By [36, Theorem 1.3.9, p.14], we can obtain

\[ \lim_{t \to +\infty} X_2(t) < \infty \quad a.s. \]

That is, \( \lim_{t \to +\infty} \left( x(t) + y(t) + \frac{p}{q}z(t) \right) < \infty \quad a.s. \), which means that there is a positive constant \( N_2 \) such that

\[ x(t) + y(t) + \frac{p}{q}z(t) \leq N_2, \quad \forall t \geq 0 \quad a.s. \]

Summarize the discussions above, we can conclude that the invariant set of model (2) is given as follows:

\[ \Omega = \left\{ X(t) \in \mathbb{R}^4_+ : 0 < x(t) + y(t) \leq \Lambda, 0 < v(t) \leq N_1, 0 < x(t) + y(t) + \frac{p}{q}z(t) \leq N_2 \right\}. \quad (6) \]

The proof is completed. \( \Box \)

**Theorem 3.2.** For any initial value \( X(0) = (x(0), y(0), v(0), z(0)) \in \mathbb{R}^4_+ \), model (2) has a unique globally positive solution \( X(t) = (x(t), y(t), v(t), z(t)), \quad t \geq 0, \) and the solution will remain in \( \mathbb{R}^4_+ \) with probability one.

**Proof.** It is obvious that the coefficients of model (2) satisfy the local Lipschitz conditions. Then, there is a unique local solution \( X(t) \) on \( (t \in [0, \tau_e)) \) for any given initial value \( X(0) \in \mathbb{R}^4_+ \), where \( \tau_e \) is the explosion time. In order to show this solution is global, we next prove \( \tau_e = \infty \quad a.s. \)

Set \( n_0 > 0 \) large enough for any initial value \( (x(0), y(0), v(0), z(0)) \) lying within the interval \( \left[ \frac{1}{n_1}, n_0 \right] \). Define the following stopping time

\[ \tau_k = \inf\{t \in [0, \tau_e) : x(t) \notin (1/n, n), y(t) \notin (1/n, n), v(t) \notin (1/n, n), z(t) \notin (1/n, n)\}, \]

**Mathematical Biosciences and Engineering**

Volume 18, Issue 1, 616–642.
where \( n \geq n_0 \). Set \( \inf \phi = \infty \), clearly, when \( n \to \infty \), \( \tau_k \) is increasing. Let \( \tau_\infty = \lim_{k \to \infty} \tau_k \), we can get \( \tau_\infty \leq \tau_e \) a.s. If there is \( \tau_\infty = \infty \) a.s., we can complete the proof at \( \tau_e = \infty \) a.s. Let us put it in another way, we can prove \( (x(t), y(t), v(t), z(t)) \in \mathbb{R}_+^4, (t \geq 0) \) a.s.

Suppose there are constants \( T > 0 \) and \( \varepsilon \in (0, 1) \) such that \( P[\tau_\infty \leq T] > \varepsilon \). So, if \( n_1 \geq n_0 \) exists, when \( n \geq n_1 \), we have \( \tau_\infty \geq T \) a.s.

Define a \( C^2 \)-function \( V: \mathbb{R}_+^4 \to \mathbb{R}_+ \):

\[
V(x, y, v, z) = \left( x - a_1 - a_1 \ln \frac{x}{a_1} \right) + \left( y - a_2 - a_2 \ln \frac{y}{a_2} \right) + c_1(v - 1 - \ln v) + c_2(z - 1 - \ln z),
\]

where \( a_1, a_2, c_1, c_2 \) are positive constants to be determined.

Using the Itô’s formula, we get:

\[
dV(x, y, v, z) = LV(x, y, v, z)dt - \sigma_1 y(x - a_1)dB_1(t) + \sigma_1 y(a_2 - v)dB_1(t)
- c_1 \sigma_2 (v - 1)dB_2(t) - c_2 \sigma_3 (z - 1)dB_3(t),
\]

where

\[
LV(x, y, v, z) = \left(1 - \frac{a_1}{x}\right) \left( \lambda_1 - d_1 x - \beta_1 x y - \beta_2 x y \right) + \left(1 - \frac{a_2}{y}\right) \left( \beta_1 x v + \beta_2 x y \right)
- ay - p y z + c_1 \left( \lambda_2 - d_2 x - d_2 y - q y z \right) + c_2 \left( \lambda_3 - d_3 x - d_3 y - q y z \right)
- \frac{a_1 \lambda_1}{x} + a_1 d_1 + a_2 \beta_1 v + a_1 \beta_2 y
+ \beta_1 x v + \beta_2 x y - ay - p y z - \frac{a_2 \beta_1 x}{y} - a_2 \beta_2 x + a_2 p z + c_1 \gamma y
- \frac{c_1 k y}{v} + c_1 \gamma + c_2 \lambda_2 - c_2 d_2 y + c_2 q y z - \frac{c_2 \lambda_2}{z} + c_2 d_2 - c_2 q y
+ \frac{1}{2} \sigma_2^2 c_1 + \frac{1}{2} \sigma_2^2 c_2 + \frac{1}{2} \sigma_3^2 d_2 - \frac{1}{2} \sigma_3^2 a_2, x^2
\]

\[
\leq \left( \lambda_1 + a_1 d_1 + a_2 + c_1 \gamma + c_2 \lambda_2 + c_2 d_2 + \frac{1}{2} \sigma_2^2 c_1 + \frac{1}{2} \sigma_3^2 c_2 \right)
+ \left( -d_1 - a_2 \beta_2 \right) x - \frac{a_1 \lambda_1}{x} + (a_1 \beta_2 - a + c_1 k - c_2 q) y
- \frac{a_2 \beta_1 x}{y} + (a_1 \beta_1 - c_1 \gamma) y - \frac{c_1 k y}{v} + (a_2 p - c_2 d_2) z - \frac{c_2 \lambda_2}{z}
+ \left( c_2 q - p \right) y z - \frac{1}{2} \sigma_2^2 a_1 \Lambda^2 + \frac{1}{2} \sigma_3^2 a_2 \Lambda^2.
\]

Choose \( a_1 = \frac{(a + p) y}{\beta_2 \gamma + \beta_1 k}, a_2 = \frac{d_1}{q}, c_1 = \frac{(a + p) \beta_1}{\beta_2 \gamma + \beta_1 k} \) and \( c_2 = \frac{p}{q} \) such that

\[
a_1 \beta_2 - a + c_1 k - c_2 q = 0, \quad a_1 \beta_1 - c_1 \gamma = 0, \quad a_2 p - c_2 d_2 = 0, \quad c_2 q - p = 0.
\]
Then,

\[
LV(x, y, v, z) \leq \left( \lambda_1 + a_1 d_1 + a a_2 + c_1 \gamma + c_2 \lambda_2 + c_2 d_2 + \frac{1}{2} \sigma^2_2 c_1 + \frac{1}{2} \sigma^2_3 c_2 \\
+ \frac{1}{2} \sigma^2_1 a_1 \Lambda^2 + \frac{1}{2} \sigma^2_2 a_2 \Lambda^2 \right) - (d_1 + a_2 \beta_2) x - \frac{a_1 a_1}{x} \\
- \frac{a_2 \beta_1 x v}{y} - \frac{c_1 k y}{v} - \frac{c_2 \lambda_2}{z}
\]

\[
\leq \lambda_1 + a_1 d_1 + a a_2 + c_1 \gamma + c_2 \lambda_2 + c_2 d_2 + \frac{1}{2} \sigma^2_2 c_1 + \frac{1}{2} \sigma^2_3 c_2 \\
+ \frac{1}{2} \sigma^2_1 a_1 \Lambda^2 + \frac{1}{2} \sigma^2_2 a_2 \Lambda^2
\]

\[
\leq K'.
\]

where \(K'\) is a positive constant. Therefore, we have

\[
dV(x, y, v, z) \leq K' dt - \sigma_1 y(x - a_1) dB_1(t) + \sigma_1 x(y - a_2) dB_1(t) \\
- c_1 \sigma_2 (v - 1) dB_2(t) - c_2 \sigma_3 (z - 1) dB_3(t).
\]

Thus,

\[
\int_0^{t_n \wedge T} dV(x, y, v, z) \leq \int_0^{t_n \wedge T} K' dt - \int_0^{t_n \wedge T} \sigma_1 y(x - a_1) dB_1(t) \\
+ \int_0^{t_n \wedge T} \sigma_1 x(y - a_2) dB_1(t) - \int_0^{t_n \wedge T} c_1 \sigma_2 (v - 1) dB_2(t) \\
- \int_0^{t_n \wedge T} c_2 \sigma_3 (z - 1) dB_3(t).
\]

Then taking the expectation on both sides, we obtain

\[
E \left[ V (x(t_n \wedge T), y(t_n \wedge T), v(t_n \wedge T), z(t_n \wedge T)) \right] \leq V(x(0), y(0), v(0), z(0)) + K' E(t_n \wedge T) \\
\leq V(x(0), y(0), v(0), z(0)) + K' T.
\]

Let \(\Omega_n = \{\tau_n \leq T\}\), where \(n \geq n_1\), then \(P(\Omega_n) \geq \varepsilon\). Note that \(\forall \omega \in \Omega_n\). By the definition of stopping time, there is at least one of \((x(t_n, \omega), y(t_n, \omega), v(t_n, \omega)\) and \(z(t_n, \omega))\) equal to \(n \) or \(-\frac{1}{n}\). Therefore,

\[
V (x(t_n, \omega), y(t_n, \omega), v(t_n, \omega), z(t_n, \omega)) \geq \left( n - a_1 - a_1 \ln \frac{n}{a_1} \right) \wedge \left( \frac{1}{n} - a_1 + a_1 \ln(a_1 n) \right) \\
\wedge \left( n - a_2 - a_2 \ln \frac{n}{a_2} \right) \wedge \left( \frac{1}{n} - a_2 + a_2 \ln(a_2 n) \right) \\
\wedge c_1 (n - 1 - \ln n) \wedge c_1 \left( \frac{1}{n} - 1 + \ln n \right) \\
\wedge c_2 (n - 1 - \ln n) \wedge c_2 \left( \frac{1}{n} - 1 + \ln n \right) \geq h(n).
\]
It then follows that

\[ V(x(0), y(0), v(0), z(0)) + K'T \geq \mathbb{E}\left[ V(x(\tau_n \wedge T), y(\tau_n \wedge T), v(\tau_n \wedge T), z(\tau_n \wedge T)) \right] \]

\[ \geq \mathbb{E}\left[ 1_{\Omega_{\omega}} V(x(\tau_n), y(\tau_n), v(\tau_n), z(\tau_n)) \right] \]

\[ \geq \varepsilon h(n), \]

where \( 1_{\Omega_{\omega}} \) is the indicator function of \( \Omega_n \). Letting \( n \to \infty \) leads to the contradiction \( \infty > V(x(0), y(0), v(0), z(0)) + K'T = \infty \), so we can conclude that \( \tau_\infty = \infty \), which completes the proof. \( \square \)

4. Stochastic extinction of the HBV infection

In this section, in order to investigate whether the HBV infection is stochastically extinct, we study the dynamics around \( E_0 \).

**Theorem 4.1.** For any given initial value \( X(0) = (x(0), y(0), v(0), z(0)) \in \Omega \), if

\[ \sigma_1^2 < \frac{2d_1}{4\Lambda^2 + \frac{\Lambda^2}{2}\left(\frac{d_1}{\Lambda} + 1\right)\left(1 + \frac{d_1}{\Lambda}\right)}, \quad \sigma_2^2 < 2\gamma, \quad \sigma_3^2 < d_2, \quad \text{and} \ R_0 \leq 1, \]

then the solution of model (2) has the following property:

\[ \limsup_{t \to +\infty} \frac{1}{t} \mathbb{E}\int_0^t \left( \left( x - \frac{\lambda_1}{d_1} \right)^2 + y^2 + v^2 + \left( z - \frac{\lambda_2}{d_2} \right)^2 \right) dt \leq \frac{M_1}{\xi}, \quad (7) \]

where

\[ M_1 := \frac{4\lambda_1^2 \sigma_1^2 \Lambda^2}{d_1^2} + \frac{2\sigma_2^2 \lambda_2^2 p^2}{q^2 d_2^2} + \frac{1}{2d_1} \left( \frac{d_1}{\lambda_1} + 1 \right) \Lambda^2 \sigma_1^2 \lambda_1 + \frac{1}{2d_1^2} \left( \frac{d_1}{\lambda_1} + 1 \right) \Lambda^2 \sigma_1^2 \lambda_1^2, \]

\[ \xi := \min \left\{ 2d_1 - \frac{\Lambda^2 \sigma_1^2}{2} \left( \frac{d_1}{\lambda_1} + 1 \right) \left( 1 + \frac{\lambda_1}{d_1} \right) + 4\sigma_2^2 \Lambda^2, \frac{a}{\Lambda}, \frac{a}{\Lambda} \frac{d_2}{q^2} (2\gamma - \sigma_2^2) \right\}. \quad (8) \]

**Proof.** Set \( \omega = x - \frac{\lambda_1}{d_1}, \quad Q = z - \frac{\lambda_2}{d_2} \), then model (2) can be rewritten as:

\[
\begin{align*}
\mathrm{d}\omega &= \left( -d_1 \omega - \beta_1v \left( \omega + \frac{\lambda_1}{d_1} \right) - \beta_2y \left( \omega + \frac{\lambda_1}{d_1} \right) - \sigma_1y \left( \omega + \frac{\lambda_1}{d_1} \right) \right) dt - \sigma_1y \left( \omega + \frac{\lambda_1}{d_1} \right) dB_1(t), \\
\mathrm{d}y &= \left( \beta_1 v \left( \omega + \frac{\lambda_1}{d_1} \right) + \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) - ay - py \left( Q + \frac{\lambda_2}{d_2} \right) \right) dt + \sigma_1y \left( \omega + \frac{\lambda_1}{d_1} \right) dB_1(t), \\
\mathrm{d}v &= \left( ky - \gamma v \right) dt - \sigma_2v dB_2(t), \\
\mathrm{d}Q &= \left( -d_2 Q + qy \left( Q + \frac{\lambda_2}{d_2} \right) \right) dt - \sigma_3 \left( Q + \frac{\lambda_2}{d_2} \right) dB_3(t).
\end{align*}
\]
Let
\[ V_1(\omega, y, v, Q) = \left( \omega + y + \frac{a}{k} v + \frac{p}{q} Q \right)^2. \]

By the Itô’s formula, we get:
\[
LV_1 = 2 \left( \omega + y + \frac{a}{k} v + \frac{p}{q} Q \right) \left( -d_1 \omega - \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) - \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) \right) \\
+ \beta_2 v \left( \omega + \frac{\lambda_1}{d_1} \right) + \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) - ay - py \left( Q + \frac{\lambda_2}{d_2} \right) + ay - \frac{ay}{k} v \\
- \frac{pd_2}{q} Q + py \left( Q + \frac{\lambda_2 y}{d_2} \right) + \frac{a^2 \sigma_2^2}{k^2} v^2 + \frac{p^2 \sigma_3^2}{q^2} \left( Q + \frac{\lambda_2}{d_2} \right)^2 \\
+ 2 \sigma_2^2 \sigma_3^2 \left( \omega + \frac{\lambda_1}{d_1} \right)^2.
\]

Noting that
\[
\frac{4 \sigma_2^2 \lambda_1^2}{d_1^2} \omega = 4 \sigma_2^2 \lambda^2 \left( \omega \cdot \frac{\lambda_1}{d_1} \right) \leq 2 \sigma_2^2 \omega^2 \Lambda^2 + \frac{2 \lambda_1^2 \sigma_1^2 \Lambda^2}{d_1^2},
\]
\[
\frac{2 \sigma_2^2 \lambda_1^2 p^2}{d_2 q^2} Q = \frac{2 \sigma_2^2 p^2}{q^2} \left( Q \cdot \frac{\lambda_2}{d_2} \right) \leq \frac{\sigma_2^2 p^2}{q^2} Q^2 + \frac{2 \lambda_1^2 \sigma_3^2 p^2}{q^2 d_2^2},
\]
then we can obtain:
\[
LV_1 \leq (4 \sigma_2^2 \lambda^2 - d_1) \omega^2 + \frac{2 \sigma_2^2 p^2}{q^2} \left( \sigma_3^2 - d_2 \right) Q^2 + \frac{a^2}{k^2} \left( \sigma_2^2 - 2 \gamma \right) v^2 + \frac{2 \sigma_2^3 \lambda_2^2 p^2}{q^2 d_2^2} + \frac{4 \sigma_2^2 \lambda_1^2 \Lambda^2}{d_1^2}.
\]

Consider a new Lyapunov function
\[
V_2(\omega, y, v, Q) = \omega + y + n v + \frac{d_1}{2 \lambda_1} \omega^2 + \frac{1}{2 \Lambda} y^2,
\]
where \( n \) is a positive constant, we compute

\[
LV_2 = -d_1 \omega - \beta_1 v \left( \omega + \frac{\lambda_1}{d_1} \right) - \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) + \left( \beta_1 v \left( \omega + \frac{\lambda_1}{d_1} \right) + \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) \right)
\]

\[
+ \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) - ay - py \left( Q + \frac{\lambda_2}{d_2} \right) + n(ky - \gamma v)
\]

\[
+ \frac{d_1 \omega}{\lambda_1} \left( -d_1 \omega - \beta_1 v \left( \omega + \frac{\lambda_1}{d_1} \right) - \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) \right)
\]

\[
+ \frac{y}{\Lambda} \left( \beta_1 v \left( \omega + \frac{\lambda_1}{d_1} \right) + \beta_2 y \left( \omega + \frac{\lambda_1}{d_1} \right) - ay - py \left( Q + \frac{\lambda_2}{d_2} \right) \right)
\]

\[
+ \frac{1}{2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \sigma_1^2 y^2 \left( \omega + \frac{\lambda_1}{d_1} \right)^2
\]

\[
\leq \left( \frac{\beta_2 \lambda_1}{d_1} - a - \frac{p \lambda_2}{d_2} + nk \right) y + \left( \beta_1 \lambda_1 \right) \frac{1}{d_1} - ny \leq \frac{a}{\Lambda} y^2
\]

\[
+ \frac{1}{2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1 \omega^2 + \frac{1}{2d_1} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1 \omega^2 + \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1
\]

\[
+ \frac{1}{2d_1^2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1.
\]

When \( R_0 \leq 1 \), we get

\[
\beta_1 \lambda_1 \frac{d_1}{\lambda_1} \leq \frac{a + \frac{p \lambda_2}{d_2} - \frac{\beta_2 \lambda_1}{d_1}}{k}.
\]

We choose \( n \) satisfying

\[
\beta_1 \lambda_1 \frac{d_1}{\lambda_1} \leq n \leq \frac{a + \frac{p \lambda_2}{d_2} - \frac{\beta_2 \lambda_1}{d_1}}{k}.
\]

Then,

\[
LV_2 \leq -\frac{a}{\Lambda} y^2 + \frac{1}{2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \omega^2 + \frac{1}{2d_1} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1 \omega^2
\]

\[
+ \frac{1}{2d_1^2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1 + \frac{1}{2d_1^2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1.
\]

Define \( V = V_1 + V_2 \), then

\[
LV \leq \left( \frac{1}{2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) + 4 \sigma_1^2 \Lambda^2 \frac{\lambda_1}{d_1} + 4 \sigma_1^2 \Lambda^2 - 2d_1 \right) \omega^2 + \frac{2p^2}{q^2} (\sigma_3^2 - d_2) Q^2
\]

\[
- \frac{a}{\Lambda} y^2 + \frac{4 \lambda_1^2 \sigma_1^2 \Lambda^2}{d_1} + \frac{4 \sigma_1^2 \Lambda^2}{d_1} \frac{\lambda_1}{d_1} + \frac{\mu^2 (\sigma_2^2 - 2\gamma) v^2}{q^2 d_2^2}
\]

\[
+ \frac{1}{2d_1} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1 + \frac{1}{2d_1^2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1.
\]

Let

\[
M_1 = \frac{4 \lambda_1^2 \sigma_1^2 \Lambda^2}{d_1^2} + \frac{2 \sigma_1^2 \lambda_1 p^2}{q^2 d_2^2} + \frac{1}{2d_1} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1 + \frac{1}{2d_1^2} \left( \frac{d_1}{\lambda_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \lambda_1.
\]
Consequently,

\[
0 \leq \mathbb{E} \left( V(\omega(t), y(t), v(t), Q(t)) \right) \leq V(\omega(0), y(0), v(0), Q(0)) + \mathbb{E} \int_0^t \left( -\frac{a}{\Lambda} y^2 + \left( \frac{d_1}{\Lambda} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \left( 1 + \frac{\lambda_1}{d_1} \right) + 4\sigma_1^2 \Lambda^2 - 2d_1 \right) \omega^2 + \frac{2p^2}{q^2} (\sigma_3^2 - d_2) Q^2 + \frac{a^2}{k^2} (\sigma_2^2 - 2\gamma) v^2 + M_1 \right) dr.
\]

Then

\[
0 \leq \mathbb{E} \int_0^t \left( \left( 2d_1 - \frac{1}{2} \left( \frac{d_1}{d_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \left( 1 + \frac{\lambda_1}{d_1} \right) + 4\sigma_1^2 \Lambda^2 \right) \right) \omega^2 + \frac{a}{\Lambda} y^2 + \frac{a^2}{k^2} (2\gamma - \sigma_2^2) v^2 + \frac{2p^2}{q^2} (d_2 - \sigma_3^2) Q^2 dr \leq V(\omega(0), y(0), v(0), Q(0)) + M_1 t.
\]

So we obtain

\[
\limsup_{t \to +\infty} \frac{1}{t} \mathbb{E} \int_0^t \left( \left( 2d_1 - \frac{1}{2} \left( \frac{d_1}{d_1} + \frac{1}{\Lambda} \right) \Lambda^2 \sigma_1^2 \left( 1 + \frac{\lambda_1}{d_1} \right) + 4\sigma_1^2 \Lambda^2 \right) \right) \omega^2 + \frac{a}{\Lambda} y^2 + \frac{a^2}{k^2} (2\gamma - \sigma_2^2) v^2 + \frac{2p^2}{q^2} (d_2 - \sigma_3^2) Q^2 dr \leq M_1.
\]

Considering the definition of \( \xi \) in Eq (8), we obtain the conclusion (7). This ends the proof. \( \square \)

**Remark 2.** From Theorem 4.1, we know that, when \( R_0 \leq 1 \), if the white noise intensity is small and satisfies

\[
\sigma_1^2 < \frac{2d_1}{4\Lambda^2 + \frac{\Lambda^2}{2} \left( \frac{d_1}{d_1} + \frac{1}{\Lambda} \right) \left( 1 + \frac{d_1}{d_1} \right)}, \quad \sigma_2^2 < 2\gamma, \quad \sigma_3^2 < d_2,
\]

the solution of the stochastic model (2) is fluctuating around the disease-free equilibrium point \( E_0 \) of model (1). Epidemiologically speaking, the HBV infection dies out with probability one.

### 5. Stochastic persistence of the HBV infection

In this section, we discuss the stochastic dynamics around the positive equilibrium \( E^* \) of the ODE HBV model (1) when \( R_0 > 1 \).

**Theorem 5.1.** For any given initial value \( X(0) = (x(0), y(0), v(0), z(0)) \in \Omega \), if \( \sigma_1^2 < \frac{d_1}{2\Lambda^2}, \sigma_2^2 < \gamma, \sigma_3^2 < \frac{d_2}{2} \) and \( R_0 > 1 \), then the solution of model (2) has the following property:

\[
\limsup_{t \to +\infty} \frac{1}{t} \mathbb{E} \int_0^t \left( (x - x^*)^2 + (y - y^*)^2 + (v - v^*)^2 + (z - z^*)^2 \right) ds \leq \frac{M_2}{\eta},
\]
Consider the following Lyapunov function

\[
V_1(x, y, v, z) = \frac{1}{2} \left( x - x^* + y - y^* + \frac{p}{q}(z - z^*) \right)^2 + \frac{p(a + d_2)}{q^2} (z - z^* - z^* \ln \frac{z}{z^*}).
\]

By using Itô’s formula, we can obtain:

\[
LV_1 = \left( x - x^* + y - y^* + \frac{p}{q}(z - z^*) \right) \left( \lambda_1 - d_1 x - a y + \frac{p a}{q} + \frac{p d}{q^2} \right) + \frac{p^2 \sigma_1^2}{q^2} z^2
\]

\[
+ \frac{p(a + d_2)}{q^2} (z - z^*) \left( \lambda_2 - d_2 + q y \right) + \frac{p(a + d_2)}{2q^2} z^* \sigma_3^2 + \sigma_1^2 x^2 y^2
\]

\[
= \left( x - x^* + y - y^* + \frac{p}{q}(z - z^*) \right) \left( d_1 x^* + a y^* + \frac{p d}{q} z^* - d_1 x - a y - \frac{p d}{q} z \right)
\]

\[
+ \frac{p^2 \sigma_1^2}{2q^2} z^2 + \frac{p(a + d_2)}{q^2} \left( \lambda_2 \left( \frac{1}{z} - \frac{1}{z^*} \right) + q(y - y^*) \right) + \frac{p(a + d_2)}{2q^2} z^* \sigma_3^2
\]

\[
+ \sigma_1^2 x^2 y^2
\]

\[
\leq -d_1(x - x^*)^2 - a(y - y^*)^2 - \frac{p^2 d^2}{q^2} (z - z^*)^2 - (a + d_1)(x - x^*)(y - y^*)
\]

\[
- \frac{p}{q} (d_1 + d_2)(x - x^*)(z - z^*) + \frac{p^2 \sigma_1^2}{2q^2} z^2 + \frac{p(a + d_2)}{2q^2} z^* \sigma_3^2 + \sigma_1^2 x^2 y^2.
\]

Consider the following Lyapunov function

\[
V_2(x, y, v, z) = \frac{1}{2}(v - v^*)^2.
\]
By Itô’s formula, when $\sigma_2^2 < \gamma$, we can obtain:

$$LV_2 = (v - v')(ky - \gamma v) + \frac{1}{2}\sigma_2^2v^2$$

$$= (v - v')(ky - \gamma v - k'y' + \gamma v') + \frac{1}{2}\sigma_2^2v^2$$

$$\leq (v - v')(k(y - y') - \gamma(v - v')) + \sigma_2^2(v - v')^2 + \sigma_2^2(v')^2$$

$$\leq \frac{\gamma - \sigma_2^2}{2}(v - v')^2 + \frac{k^2}{2(\gamma - \sigma_2^2)}(y - y')^2 - (\gamma - \sigma_2^2)(v - v')^2 + \sigma_2^2(v')^2$$

$$\leq \frac{k^2}{2(\gamma - \sigma_2^2)}(y - y')^2 - \frac{\gamma - \sigma_2^2}{2}(v - v')^2 + \sigma_2^2(v')^2$$

Define $W_1 = V_1 + \frac{a(y - \sigma_2^2)}{2k^2}V_2$, then

$$LW_1 \leq -d_1(x - x')^2 - a(y - y')^2 - \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v')^2 - \frac{p^2d_2}{q^2}(z - z')^2$$

$$+ \frac{a}{4}(y - y')^2 - (a + d_1)(x - x')(y - y') + \frac{a(y - \sigma_2^2)}{2k^2}\sigma_2^2(v')^2$$

$$- \frac{p}{q}(d_1 + d_2)(x - x')(z - z') + \frac{p^2}{2q^2}\sigma_3^2z^2 + \frac{p(a + d_2)}{2q^2}z^\ast\sigma_3^2 + \sigma_1^2x^2y^2$$

$$\leq -d_1(x - x')^2 - a(y - y')^2 - \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v')^2 - \frac{p^2d_2}{q^2}(z - z')^2$$

$$+ \frac{a}{4}(y - y')^2 + (a + d_1)^2(x - x')^2 + \frac{a}{4}(y - y')^2 + \frac{(d_1 + d_2)^2}{2d_2}(x - x')^2$$

$$+ \frac{p^2d_2}{2q^2}(z - z')^2 + \frac{a(y - \sigma_2^2)}{2k^2}\sigma_2^2(v')^2 + \frac{p^2}{2q^2}\sigma_3^2z^2 + \frac{p(a + d_2)}{2q^2}z^\ast\sigma_3^2 + \sigma_1^2x^2y^2$$

$$\leq \left(\frac{(a + d_1)^2}{a} + \frac{(d_1 + d_2)^2}{2d_2} - d_1\right)(x - x')^2 - \frac{a}{2}(y - y')^2 + \frac{p^2}{2q^2}\sigma_3^2z^2$$

$$- \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v')^2 - \frac{p^2d_2}{2q^2}(z - z')^2 + \frac{a(y - \sigma_2^2)}{2k^2}\sigma_2^2(v')^2 + \frac{p(a + d_2)}{2q^2}z^\ast\sigma_3^2$$

$$+ \sigma_1^2x^2y^2.$$

Consider a new Lyapunov function

$$V_3(x, y, v, z) = x - x' - x'\ln \frac{x}{x'} + \left(y - y' - y'\ln \frac{y}{y'}\right) + \frac{\beta_1 x'v'}{ky'} \left(v - v' - v'\ln \frac{v}{v'}\right)$$

$$+ \frac{p}{q} \left(z - z' - z'\ln \frac{z}{z'}\right).$$
Applying Itô’s formula, we get:

\[
\begin{align*}
dV_3(x, y, v, z) &= LV_3(x, y, v, z)dt - \sigma_1 y(x - x^*)dB_1(t) + \sigma_1 x(y - y^*)dB_1(t) \\
&= -\frac{\sigma_2 \beta_1 x' v^*}{ky^*} (v - v^*)dB_2(t) - \frac{p \sigma_3}{q} (z - z^*)dB_3(t),
\end{align*}
\]

where

\[
LV_3 = \left(1 - \frac{x^*}{x}\right)(\lambda_1 - d_1 x - \beta_1 x v - \beta_2 x y) + \left(1 - \frac{y^*}{y}\right)(\beta_1 x v + \beta_2 x y - ay - p y z) \\
+ \frac{\beta_1 x'^*}{ky^*} \left(1 - \frac{v^*}{v}\right) (ky - y v) + \frac{p}{q} \left(1 - \frac{z^*}{z}\right) (\lambda_2 - d_2 z + q y z) \\
+ \frac{\sigma_2^2 \beta_1 x'^* (v^*)^2}{2ky^*} + \frac{\sigma_3^2 p z^*}{2q} + \frac{1}{2} \sigma_1^2 x'^2 + \frac{1}{2} \sigma_2^2 y'^2 \\
= \left(1 - \frac{x^*}{x}\right) (-d_1 (x - x^*) - \beta_1 (x v - x^* v^*) - \beta_2 (x y - x^* y^*)) + \frac{\sigma_2^2 p z^*}{2q} \\
+ \frac{\beta_1 x'^* (v - v^*)}{y^*} \left(\frac{y}{v} - \frac{y^*}{v^*}\right) + (y - y^*) \left(\frac{x v}{y} - \frac{x^* v^*}{y^*}\right) + \beta_2 (x - x^*) \\
- p(z - z^*) + \frac{\sigma_2^2 \beta_1 x'^* (v^*)^2}{2ky^*} + \frac{p}{q} (z - z^*) \left(\lambda_2 \left(\frac{1}{z} - \frac{1}{z^*}\right) + q (y - y^*)\right) \\
+ \frac{1}{2} \sigma_1^2 x'^2 + \frac{1}{2} \sigma_2^2 y'^2 \\
= -d_1 x^* \left(\frac{x^*}{x} + \frac{x}{x^*} - 2\right) + \frac{p \lambda_2}{q} \left(2 - \frac{z}{z^*} - \frac{z^*}{z}\right) - \beta_2 x^* y^* \left(\frac{x^*}{x} + \frac{x}{x^*} - 2\right) \\
+ \beta_1 x'^* \left(3 - \frac{x^*}{x} - \frac{v^* y}{y^* v} - \frac{y^* x v}{x^* v^*}\right) + \frac{\sigma_2^2 \beta_1 x'^* (v^*)^2}{2ky^*} + \frac{\sigma_3^2 p z^*}{2q} \\
+ \frac{1}{2} \sigma_1^2 x'^2 + \frac{1}{2} \sigma_2^2 y'^2 \\
\leq -d_1 x^* \left(\frac{x^*}{x} + \frac{x}{x^*} - 2\right) + \frac{p \lambda_2}{q} \left(\frac{z}{z^*} + \frac{z^*}{z} - 2\right) + \frac{\sigma_2^2 \beta_1 x'^* (v^*)^2}{2ky^*} + \frac{\sigma_3^2 p z^*}{2q} \\
+ \frac{1}{2} \sigma_1^2 x'^2 + \frac{1}{2} \sigma_2^2 y'^2 \\
\leq -\frac{d_1}{\Lambda} (x - x^*)^2 + \frac{\sigma_2^2 \beta_1 x'^* (v^*)^2}{2ky^*} + \frac{\sigma_3^2 p z^*}{2q} + \frac{1}{2} \sigma_1^2 x'^2 + \frac{1}{2} \sigma_2^2 y'^2.
\]
Define $W_2 = W_1 + hV_3$, then

$$LW_2 \leq \left( \frac{(a + d_1)^2}{a} + \frac{(d_1 + d_2)^2}{2d_2} - \frac{d_1 h}{\Lambda} - d_1 \right)(x - x^*)^2 - \frac{a}{2}(y - y^*)^2 - \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v^*)^2 - \frac{p^2d_2}{2q^2}(z - z^*)^2 + \frac{a(y - \sigma_2^2)^2}{2k^2}(v^*)^2 + \frac{p^2}{2q^2}\sigma_3^2z^2$$

$$+ h\left( \frac{1}{2}\sigma_2^2x^*\Lambda^2 + \frac{1}{2}\sigma_1^2y^*\Lambda^2 + \frac{a^2\beta_1 x^*(v^*)^2}{2ky^*} + \frac{\sigma_3^2p z_1^*}{2q} \right) + \frac{p(a + d_2)}{2q^2}z^*\sigma_3^2 + \sigma_1^2x^*y^2.$$

Choosing

$$h = \frac{\Lambda}{d_1}\left( \frac{(a + d_1)^2}{a} + \frac{(d_1 + d_2)^2}{2d_2} - \frac{d_1 h}{\Lambda} - d_1 \right)$$

such that \( \frac{(a + d_1)^2}{a} + \frac{(d_1 + d_2)^2}{2d_2} = \frac{d_1 h}{\Lambda} \), we have:

$$LW_2 \leq -d_1(x - x^*)^2 - \frac{a}{2}(y - y^*)^2 - \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v^*)^2 - \frac{p^2d_2}{2q^2}(z - z^*)^2 + \frac{a(y - \sigma_2^2)^2}{2k^2}(v^*)^2 + \frac{p^2}{2q^2}\sigma_3^2z^2$$

$$+ h\left( \frac{1}{2}\sigma_2^2x^*\Lambda^2 + \frac{1}{2}\sigma_1^2y^*\Lambda^2 + \frac{a^2\beta_1 x^*(v^*)^2}{2ky^*} + \frac{\sigma_3^2p z_1^*}{2q} \right) + \frac{p(a + d_2)}{2q^2}z^*\sigma_3^2 + \frac{p^2d_2}{2q^2}(z - z^*)^2.$$

Because \( a^2 \leq 2(a - b)^2 + 2b^2 \), we can get:

$$LW_2 \leq (2\sigma_1^2\Lambda^2 - d_1)(x - x^*)^2 - \frac{a}{2}(y - y^*)^2 - \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v^*)^2 + \frac{p^2d_2}{2q^2}(z - z^*)^2 + \frac{a^2\beta_1 x^*(v^*)^2}{2ky^*} + \frac{\sigma_3^2p z_1^*}{2q} \right) + \frac{p(a + d_2)}{2q^2}z^*\sigma_3^2 + \frac{p^2d_2}{2q^2}(z - z^*)^2.$$

Let

$$M_2 = 2\sigma_1^2(x^*)^2\Lambda^2 + \frac{a(y - \sigma_2^2)^2}{2k^2}\sigma_2^2(v^*)^2 + \frac{p^2}{2q^2}\sigma_3^2(z^*)^2 + \frac{p(a + d_2)}{2q^2}z^*\sigma_3^2$$

$$+ h\left( \frac{1}{2}\sigma_2^2x^*\Lambda^2 + \frac{1}{2}\sigma_1^2y^*\Lambda^2 + \frac{a^2\beta_1 x^*(v^*)^2}{2ky^*} + \frac{\sigma_3^2p z_1^*}{2q} \right),$$

and we can derive that

$$LW_2 \leq (2\sigma_1^2\Lambda^2 - d_1)(x - x^*)^2 - \frac{a}{2}(y - y^*)^2 - \frac{a(y - \sigma_2^2)^2}{4k^2}(v - v^*)^2 + \frac{p^2}{2q^2}\left( \frac{\sigma_3^2 - d_2}{2} \right)(z - z^*)^2 + M_2.$$
As a result,
\[
\begin{align*}
dW_2 &\leq LW_2 dt - \frac{p}{q} \left( x - x^* + y - y^* + \frac{p}{q}(z - z^*) \right) \sigma_3 z dB_3(t) - \frac{a(y - \sigma_2^2)}{2k^2} (y - v^*) \sigma_2 y dB_2(t) \\
&\quad - \frac{h\beta_1 x^* v^*}{ky^*} (v - v^*) \sigma_3 dB_2(t) - \frac{hp}{q} (z - z^*) \sigma_3 dB_3(t) - \frac{p \sigma_3 (a + d_2)}{q^2} (z - z^*) dB_3(t) \\
&\quad - h(x - x^*) \sigma_1 y dB_1(t) + h(y - y^*) \sigma_1 x dB_1(t).
\end{align*}
\]

By integrating both sides from 0 to \( t \) and then taking the expectation on both sides, it yields
\[
0 \leq \mathbb{E} (W_2(x(t), y(t), v(t), z(t)))
\]
\[
\leq W_2(0, 0, 0, 0) + \mathbb{E} \int_0^t \left( (2 \sigma_1 \Lambda^2 - d_1) (x - x^*)^2 - \frac{a}{2} (y - y^*)^2 \\
- \frac{a(y - \sigma_2^2)}{4k^2} (v - v^*)^2 + \frac{p^2}{q^2} \left( \frac{d_2}{2} - \sigma_3^2 \right) (z - z^*)^2 + M_2 \right) ds.
\]

Then, we can get
\[
\mathbb{E} \int_0^t \left( (d_1 - 2 \sigma_1 \Lambda^2) (x - x^*)^2 + \frac{a}{2} (y - y^*)^2 + \frac{a(y - \sigma_2^2)}{4k^2} (v - v^*)^2 \\
+ \frac{p^2}{q^2} \left( \frac{d_2}{2} - \sigma_3^2 \right) (z - z^*)^2 \right) ds \leq W_2(0, 0, 0, 0) + M_2 t.
\]

And hence, there is
\[
\limsup_{t \to +\infty} \frac{1}{t} \mathbb{E} \int_0^t \left( (d_1 - 2 \sigma_1 \Lambda^2) (x - x^*)^2 + \frac{a}{2} (y - y^*)^2 + \frac{a(y - \sigma_2^2)}{4k^2} (v - v^*)^2 \\
+ \frac{p^2}{q^2} \left( \frac{d_2}{2} - \sigma_3^2 \right) (z - z^*)^2 \right) ds \leq M_2.
\]

Let
\[
\eta = \min \left\{ d_1 - 2 \sigma_1 \Lambda^2, \frac{a}{2}, \frac{a(y - \sigma_2^2)}{4k^2}, \frac{p^2}{q^2} \left( \frac{d_2}{2} - \sigma_3^2 \right) \right\},
\]
then
\[
\limsup_{t \to +\infty} \frac{1}{t} \mathbb{E} \int_0^t \left( (x - x^*)^2 + (y - y^*)^2 + (v - v^*)^2 + (z - z^*)^2 \right) ds \leq \frac{M_2}{\eta}.
\]

\[\square\]

**Remark 3.** From Theorem 5.1, we know that, when \( R_0 > 1 \), if the noise intensity is small and satisfies
\[
\sigma_1^2 < \frac{d_1}{2\Lambda^2}, \quad \sigma_2^2 < \gamma, \quad \sigma_3^2 < \frac{d_2}{2},
\]
then the solution of the stochastic model (2) fluctuates around the infection equilibrium \( E^* \) of the deterministic model (1). Epidemiologically, the HBV infection persist with probability one.
6. Numerical simulations

In this section, we continue to study the SDE model (2) through a numerical approach. We aim to investigate how environmental fluctuations affect disease spreading on the HBV dynamics.

We employ the Milstein’s method [37] to simulate the SDE model (2), whose numerical scheme for the SDE model (2) is given by

\[
\begin{align*}
x_{i+1} &= x_i + (\lambda_1 - d_1 x_i - \beta_1 x_i y_i - \beta_2 x_i y_i)\Delta t - \sigma_1 x_i y_i \sqrt{\Delta t} \xi_i - \frac{\sigma_1^2}{2} x_i y_i (\Delta t \xi_i^2 - \Delta t), \\
y_{i+1} &= y_i + (\beta_1 x_i y_i + \beta_2 x_i y_i - \alpha y_i - p y_i z_i)\Delta t + \sigma_1 x_i y_i \sqrt{\Delta t} \xi_i + \frac{\sigma_1^2}{2} x_i y_i (\Delta t \xi_i^2 - \Delta t), \\
v_{i+1} &= v_i + (k y_i - q y_i)\Delta t - \sigma_2 v_i \sqrt{\Delta t} \xi_i - \frac{\sigma_2^2}{2} v_i (\Delta t \xi_i^2 - \Delta t), \\
z_{i+1} &= z_i + (\lambda_2 - d_2 z_i + q y_i z_i)\Delta t - \sigma_3 z_i \sqrt{\Delta t} \xi_i - \frac{\sigma_3^2}{2} z_i (\Delta t \xi_i^2 - \Delta t),
\end{align*}
\]

where \(\xi_i, \xi_i, \xi_i, i = 1, 2, \ldots, n\) are Gaussian random variables. We choose \(\Delta t = 0.01\).

As an example, the parameters are taken as follows:

\[
\begin{align*}
\lambda_1 &= 0.3, d_1 = 0.25, \beta_1 = 0.4, a = 0.2, p = 0.2, k = 0.06, \\
\gamma &= 0.1, q = 0.15, d_2 = 0.1, \beta_2 = 0.3, \lambda_2 = 0.2.
\end{align*}
\]

Then we obtain

\[
R_0 = \frac{\lambda_1 d_2 \left( \frac{k d_1}{\gamma} + \beta_2 \right)}{d_1 (a d_2 + \lambda_2 p)} = 1.08 > 1,
\]

and the corresponding deterministic model (1) has a disease-free equilibrium \(E_0 = (1.2, 0, 0, 2.0)\) and a unique epidemic equilibrium \(E^* = (1.140, 0.025, 0.015, 2.077)\), which is globally asymptotically stable according to Theorem 2.1.

Next, we use different values of \(\sigma_i (i = 1, 2, 3)\) to understand the role of the noise strength in the resulting HBV dynamics for the SDE model (2).

**Example 1:** We adopt \((\sigma_1, \sigma_2, \sigma_3) = (0.15, 0.08, 0.1)\) and \((0.2, 0.1, 0.15)\), respectively, then simple computations show that \(\sigma_1^2 < 0.056, \sigma_2^2 < 0.100, \sigma_3^2 < 0.050\), hence the conditions in Theorem 5.1 hold. From Theorem 5.1, we know that the HBV persist with probability one. The numerical results are shown in Figures 1 and 2, we know that, after some initial transients the solutions \(x(t), y(t), v(t), z(t)\) of the SDE model (2) fluctuation around the endemic equilibrium \(E^* = (1.140, 0.025, 0.015, 2.077)\) of the deterministic model (1). Comparing Figures 1 and 2, we can see that, if the noise is lower, the amplitude of fluctuation is small (Figure 1); while if the noise is higher, the amplitude of fluctuation is big (Figure 2).
Figure 1. The paths of $x(t)$, $y(t)$, $v(t)$, $z(t)$ for the stochastic model (2) when $\sigma_1 = 0.15$, $\sigma_2 = 0.08$, $\sigma_3 = 0.1$ and $R_0 > 1$.

For the sake of learning the impact of random perturbation on the HBV disease dynamics, we have repeated the simulation 10000 times keeping all parameters fixed and never observed any extinction scenario up to $t = 100$. And we give the histogram of the approximate stationary distributions of $x(t)$ (a), $y(t)$ (b), $v(t)$ (c) and $z(t)$ (d) at $t = 100$ for the stochastic model (2) with $\sigma_1 = 0.15$, $\sigma_2 = 0.08$ and $\sigma_3 = 0.1$ (Figure 3) and $\sigma_1 = 0.2$, $\sigma_2 = 0.1$ and $\sigma_3 = 0.15$ (Figure 4), respectively (the numerical method can be found in [23]). One can find that $x(t)$, $y(t)$, $v(t)$ and $z(t)$ distributes normally, and also the solution to the SDE model (2) suggests for lower $\sigma_i$ ($i = 1, 2, 3$), the amplitude of fluctuation is slight and the oscillations are more symmetrically distributed (Figure 3); while for higher $\sigma_i$ that the amplitude of fluctuation is remarkable and the distribution of the solution is skewed (Figure 4).

Example 2: If we adopt $(\sigma_1, \sigma_2, \sigma_3) = (0.8, 0.65, 0.6)$, then $\sigma_1^2 > 0.056$, $\sigma_2^2 > 0.100$, $\sigma_3^2 > 0.050$, obviously, the conditions of Theorem 5.1 are not satisfied. The numerical results are shown in Figure 5, which suggest that the HBV infection dies out with probability one. That is, in the case of $R_0 > 1$, if the environmental forcing intensity $\sigma_i$ ($i = 1, 2, 3$) is so large that the conditions of Theorem 5.1 are not satisfied, the HBV could die out with probability one. Obviously, the extinction of the HBV is induced by the noise.

Form Example 2, we know that in the case of $R_0 > 1$, there exists extinction of the HBV infection in the SDE model (2). Next, we will focus on the extinction time of the HBV infection in the stochastic model (2).

Example 3: We adopt $(\sigma_2, \sigma_3) = (0.65, 0.6)$, then $\sigma_2^2 - \gamma = 0.32$, $\sigma_3^2 - \frac{d_2}{4} = 0.31$. Obviously, the conditions of Theorem 5.1 are not satisfied. And we repeat 10,000 simulations with the same
Figure 2. The paths of $x(t), y(t), v(t), z(t)$ for the stochastic model (2) when $\sigma_1 = 0.2, \sigma_2 = 0.1, \sigma_3 = 0.15$ and $R_0 > 1$.

Figure 3. Histogram of the probability density function for $x(t)$ (a), $y(t)$ (b), $v(t)$ (c) and $z(t)$ (d) population at $t = 100$ for the stochastic model (2) with $\sigma_1 = 0.15, \sigma_2 = 0.08, \sigma_3 = 0.1$.

Figure 4. Histogram of the probability density function for $x(t)$ (a), $y(t)$ (b), $v(t)$ (c) and $z(t)$ (d) population at $t = 100$ for the stochastic model (2) with $\sigma_1 = 0.2, \sigma_2 = 0.1, \sigma_3 = 0.15$. 
Figure 5. The paths of $x(t), y(t), v(t), z(t)$ for the stochastic model (2) when $\sigma_1 = 0.8, \sigma_2 = 0.65, \sigma_3 = 0.6$ and $R_0 > 1$.

parameters as in Figure 5, we can calculate the average extinction time of $y(t)$ with $\sigma_1$, and the results are shown in Figure 6. For example, when $\sigma_1 = 0.4$, the average extinction time for $y(t)$ is 196.6; when $\sigma_1 = 0.8$, it is 79.6. We can conclude that the average extinction time decreases with the increase of noise intensity $\sigma_1$.

Figure 6. The average extinction time for $y(t)$ in the SDE model (2) with respect to $\sigma_1$.

Finally, we will investigate the effect of the effective contact rate $\beta_2$ on the HBV dynamics of the
SDE HBV model (2) with fixed forcing intensity.

**Example 4:** We fix \((\sigma_1, \sigma_2, \sigma_3) = (0.1, 0.1, 0.1)\), and choose \(\beta_2 = 0.15, 0.2, 0.25, 0.35, 0.4, 0.45\), other parameters are taken as in parameter set (11). In this case, we can obtain

\[
\begin{align*}
\sigma_1^2 - \frac{2d_1}{4\Lambda^2 + \frac{\Lambda^2}{2} \left( \frac{d_1}{d_1} + \frac{1}{\gamma} \right) (1 + \frac{d_1}{d_1})} &= -0.03 < 0, \\
\sigma_2^2 - 2\gamma &= -0.19 < 0, \\
\sigma_3^2 - d_2 &= -0.09 < 0, \\
\sigma_3^2 - \frac{d_1}{2\Lambda^2} &= -0.05 < 0, \\
\sigma_3^2 - \gamma &= -0.09 < 0, \\
\sigma_3^2 - \frac{d_2}{2} &= -0.04 < 0
\end{align*}
\]

and the values of \(R_0\) are given in Table 1. Obviously, the cases of \(\beta_2 = 0.15, 0.2, 0.25\) satisfy the conditions of Theorem 4.1, and the cases of \(\beta_2 = 0.35, 0.4, 0.45\) satisfy the conditions of Theorem 5.1. The numerical results of the stochastic extinction and persistence of model (2) are shown in Figure 7.

**Table 1.** The values of \(R_0\) with different values of \(\beta_2\).

| \(\beta_2\) | 0.15 | 0.2 | 0.25 | 0.35 | 0.4 | 0.45 |
|---|---|---|---|---|---|---|
| \(R_0\) | 0.78 | 0.88 | 0.98 | 1.18 | 1.28 | 1.38 |

**Figure 7.** The path of \(y(t)\) for the stochastic model (2) when \(\sigma_1 = 0.1, \sigma_2 = 0.1, \sigma_3 = 0.1\).

### 7. Conclusions

For the study of an HBV infection model, much attention is usually paid to the persistence and extinction of HBV infection. In the deterministic HBV model, the value of the basic reproductive
number is usually the key to determining the persistent and extinction of the HBV. When \( R_0 \leq 1 \), the HBV will die out; when \( R_0 > 1 \), the HBV will persist (see Theorem 2.1). But the SDE HBV model, such as model (2), does not have any equilibrium, so we have to study the asymptotic behavior of the solution of the SDE model around the equilibrium of the deterministic HBV model to reflect the trend of the HBV infection to some extent.

In the present paper, we investigate the stochastic dynamics of an HBV infection model with cell-to-cell transmission and CTL immune response, and analyze the stochastic fluctuation of positive solutions of SDE model (2) around the infection-free equilibrium \( E_0 \) (Figures 7(a)–7(c)) and the infection equilibrium \( E^* \) (Figures 1, 2 and Figure 7(d)–7(f)) of the deterministic model (1), respectively, which reveals that the influence of the white noise on HBV dynamics. More precisely, when the deterministic model (1) is disturbed by small white noise \( \sigma_i (i = 1, 2, 3) \), the HBV infection is extinct (see Theorem 4.1 and Remark 2) or persist (see Theorem 5.1 and Remark 3), and the solutions of model (2) will fluctuate around the infection equilibrium \( E^* \) of the deterministic model (1). Furthermore, via numerical simulations, we find that the fluctuation amplitude is positively related to the intensity of the white noise, which means, epidemiologically, as the intensity of white noise decreases, the fluctuation of the solution of model (2) around the equilibrium of the corresponding deterministic model (1) becomes smaller and smaller (Figures 1–4). In these cases, to a great extent, we can ignore the noise and use the deterministic model (2) to describe the HBV infection dynamics. However, when the noise \( \sigma_i (i = 1, 2, 3) \) is sufficiently large, the infected hepatocytes \( y(t) \) on relatively large disturbance of white noise goes to extinction, and the uninfected hepatocytes \( x(t) \) generates persistence (Figure 5). In these cases, we cannot ignore the effect of noise, that is, we should use the stochastic HBV model (2) rather than the deterministic model (1) to describe the HBV infection dynamics. In addition, it should be pointed out that the increase in \( \beta_2 \) results in the corresponding increase in \( R_0 \). From the biological point of view, one can find that under certain forcing intensity, reducing the value of the effective contact rate \( \beta_2 \) so that the value of \( R_0 \) is less than unity could lead to the stochastically extinction of the HBV infection. These results can provide us with some useful control strategies to regulate HBV infection dynamics.

Acknowledgements

The authors would like to thank the anonymous referees for very helpful suggestions and comments which led to improvements of our original manuscript. This research was supported by the National Natural Science Foundation of China (Grant numbers 61672013, 11601179 and 12071173), and the Huaian Key Laboratory for Infectious Diseases Control and Prevention (HAP201704). K.F. Wang was supported by the National Natural Science Foundation of China (Grant number 11771448).

Conflict of interest

The authors declare that they have no competing interests.

References

1. World Health Organization, Hepatitis B, Accessed 12 Nov. 2020. Available from: https://www.who.int/health-topics/hepatitis#tab=tab_1.
2. M. Nowak, R. M. May, Population dynamics of immune responses to persistent viruses, *Science*, 272 (1996), 74–79.

3. R. A. Arnaout, M. A. Nowak, Competitive coexistence in antiviral immunity, *J. Theor. Biol.*, 204 (2000), 431–441.

4. R. V. Culshaw, S. Ruan, R. J. Spiteri, Optimal HIV treatment by maximising immune response, *J. Math. Biol.*, 48 (2004), 545–562.

5. D. Bertacchi, F. Zucca, S. Foresti, D. Mangioni, A. Gori, Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach, *Math. Med. Biol.*, 32 (2015), 383–403.

6. A. U. Neumann, Hepatitis B viral kinetics: A dynamic puzzle still to be resolved, *Hepatology*, 42 (2005), 249–254.

7. M. Nowak, R. M. May, *Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology*, Oxford University Press, UK, 2000.

8. J. Li, K. Men, Y. Yang, D. Li, Dynamical analysis on a chronic hepatitis C virus infection model with immune response, *J. Theor. Biol.*, 365 (2015), 337–346.

9. M. Li, J. Zu, The review of differential equation models of HBV infection dynamics, *J. Virol. Meth.*, 266 (2019), 103–113.

10. A. Mojaver, H. Kheiri, Dynamical analysis of a class of hepatitis C virus infection models with application of optimal control, *Inter. J. Biomath.*, 9 (2016), 1650038.

11. W. Mothes, N. M. Sherer, J. Jin, P. Zhong, Virus cell-to-cell transmission, *J. Virol.*, 84 (2010), 8360–8368.

12. S. Pan, S. P. Chakrabarty, Threshold dynamics of HCV model with cell-to-cell transmission and a non-cytolytic cure in the presence of humoral immunity, *Commun. Nonlinear Sci.*, 61 (2018), 180–197.

13. K. Razali, H. Thein, J. Bell, M. Cooper-Stanbury, K. Dolan, G. Dore, et al., Modelling the hepatitis C virus epidemic in Australia, *Drug Alcohol Depen.*, 91 (2007), 228–235.

14. B. Roe, W. W. Hall, Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus, *Expert Rev. Mol. Med.*, 10 (2008), e30.

15. F. Zhang, J. Li, C. Zheng, L. Wang, Dynamics of an HBV/HCV infection model with intracellular delay and cell proliferation, *Commun. Nonlinear Sci.*, 42 (2017), 464–476.

16. P. Zhong, L. M. Agosto, J. B. Munro, W. Mothes, Cell-to-cell transmission of viruses, *Curr. Opin. Virol.*, 3 (2013), 44–50.

17. M. Sourisseau, N. Sol-Foulon, F. Porrot, F. Blanchet, O. Schwartz, Inefficient human immunodeficiency virus replication in mobile lymphocytes, *J. Virol.*, 81 (2006), 1000–1012.

18. B. Monel, E. Beaumont, D. Vendrame, O. Schwartz, D. Brand, Hiv cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores, *J. Virology*, 86 (2012), 3924–3933.

19. Y. Yang, Q. Han, Z. Hou, C. Zhang, Z. Tian, J. Zhang, Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction, *Cell. Mol. Immunol.*, 14 (2017), 465–475.

20. G. Bocharov, B. Ludewig, A. Bertoletti, P. Klenerman, T. Junt, P. Krebs, et al., Underwhelming the immune response: effect of slow virus growth on CD8+ T-lymphocyte responses, *J. Virol.*, 78 (2004), 2247–2254.
21. S. Cai, Y. Cai, X. Mao, A stochastic differential equation SIS epidemic model with two independent brownian motions, *J. Math. Anal. Appl.*, 474 (2019), 1536–1550.

22. Y. Cai, J. Jiao, Z. Gui, Y. Liu, W. M. Wang, Environmental variability in a stochastic epidemic model, *Appl. Math. Comp.*, 329 (2018), 210–226.

23. Y. Cai, Y. Kang, M. Banerjee, W.M. Wang, A stochastic SIRS epidemic model with infectious force under intervention strategies, *J. Differ. Equations*, 259 (2015), 7463–7502.

24. Y. Cai, Y. Kang, W. M. Wang, A stochastic SIRS epidemic model with nonlinear incidence rate, *Appl. Math. Comp.*, 305 (2017), 221–240.

25. C. Ji, D. Jiang, Dynamics of an HIV-1 infection model with cell-mediated immune response and stochastic perturbation, *Inter. J. Biomath.*, 5 (2012), 1250039.

26. T. Luzyanina, G. Bocharov, Stochastic modeling of the impact of random forcing on persistent hepatitis B virus infection, *Math. Comp. Simul.*, 96 (2014), 54–65.

27. F. A. Rihan, H. J. Alsakaji, C. Rajivganthi, Stochastic SIRC epidemic model with time-delay for covid-19, *Adv. Differ. Equ.*, 2020 (2020), 502.

28. Y. Wang, D. Jiang, Stationary distribution and extinction of a stochastic viral infection model, *Discrete Dyn. Nat. Soc.*, 2017 (2017), 1–13.

29. Y. Wang, D. Jiang, A. Alsaeedi, T. Hayat, Modelling a stochastic HIV model with logistic target cell growth and nonlinear immune response function, *Phys. A*, 501 (2018), 276–292.

30. Y. Wang, D. Jiang, T. Hayat, B. Ahmad, A stochastic HIV infection model with T-cell proliferation and CTL immune response, *Appl. Math. Comp.*, 315 (2017), 477–493.

31. Y. Yuan, L. J. S. Allen, Stochastic models for virus and immune system dynamics, *Math. Biosci.*, 234 (2011), 84–94.

32. F. Xie, M. Shan, X. Lian, W. M. Wang, Periodic solution of a stochastic HBV infection model with logistic hepatocyte growth, *Appl. Math. Comp.*, 293 (2017), 630–641.

33. T. G. Kurtz, Solutions of ordinary differential equations as limits of pure jump Markov processes, *J. Appl. Probab.*, 7 (1970), 49–58.

34. T. G. Kurtz, Limit theorems for sequences of jump Markov processes approximating ordinary differential processes, *J. Appl. Probab.*, 8 (1971), 344–356.

35. P. Van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, *Math. Biosci.*, 180 (2002), 29–48.

36. X. Mao, *Stochastic Differential Equations and Applications*, Elsevier, 2007.

37. D. J. Higham, An algorithmic introduction to numerical simulations of stochastic differential equations, *SIAM Rev.*, 43 (2001), 525–546.